Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Inclusion Criteria: * healthy adult subjects aged 18 to 50 years inclusive, who are able and willing to give informed consent, following a detailed explanation of participation in protocol * available for the duration of the study and available for scheduled and potential additional visits Exclusion Criteria: * women who are pregnant, breast-feeding or of childbearing potential and unwilling to use a reliable method of contraception throughout the study period * history of anaphylactic shock following vaccination by any route have phenylketonuria * hypersensitivity to any component of the vaccine or are hypersensitive to two of the following antibiotics: ciprofloxacin, azithromycin, ampicillin, trimethoprim sulfamethoxazole * received antibiotic medication within 14 days prior to dosing * received any vaccine within 4 weeks prior to dosing or plan to receive a vaccine within 4 weeks after dosing * received any vaccine against Salmonella typhi (licensed or investigational) or ever suffered from typhoid fever * subjects who test positive for hepatitis B, hepatitis C, HIV or human leucocyte antigen B-27 * known or suspected history of liver or active gall bladder disease, ongoing gastro-intestinal disease or abnormality * commercial food handlers or health care workers with direct contact with high risk patients or who have household contacts with immuno-compromised individuals, pregnant women or children less than 2 years of age * subjects who have a clinically significant amount of protein or haemoglobin in their urine or abnormality of their haematology or serum biochemistry parameters * impairment of immune function or those receiving or have received cytotoxic drugs in the 6 months prior to study entry * subjects who use antacids, proton pump inhibitors or H2 blockers on a regular basis or have consumed proton pump inhibitors or H2 blockers within 24 hours prior to dosing * acute infections (including fever of 37.5 degrees Celsius or greater) on the day of dosing. * subjects with chronic disease (e.g Crohn's disease, inflammatory bowel disease, diabetes) who cannot withstand a 3 hour fast * substance abuse or a history of substance abuse that might interfere with participation in the study * body mass index (BMI) is less than 19 or greater than 34 kg per m2 * clinically significant medical condition that precludes participation in the study * subjects who have participated in an interventional clinical trial within 60 days of dosing